Free Trial
OTCMKTS:SIGY

Sigyn Therapeutics Q3 2025 Earnings Results & Report

Sigyn Therapeutics logo
$0.03 -0.01 (-16.67%)
As of 03:59 PM Eastern

Sigyn Therapeutics reported Q3 2025 earnings on November 14, 2025. The company reported EPS of -$0.36.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes

Sigyn Therapeutics EPS Results

Actual EPS
-$0.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Sigyn Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Sigyn Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026, based on past reporting schedules.

Conference Call Resources

Sigyn Therapeutics Q3 2025 Earnings FAQ

Sigyn Therapeutics (OTCMKTS:SIGY) reported earnings of -$0.36 per share for Q3 2025. The report was announced on Friday, November 14, 2025.

Sigyn Therapeutics' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Sigyn Therapeutics on the company's earnings history page.

Sigyn Therapeutics Earnings Headlines

SIGY Sigyn Therapeutics Inc.
Palantir and Wall Street are in on it…
Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has poured billions into this firm, which may have found a solution to the growing AI energy crunch. Unlike pricey chipmakers trading at 40 times earnings, this pure-play AI energy name remains cheap and profitable. See the name and ticker behind this fast-moving story before wider attention catches on.tc pixel
Sigyn Therapeutics Delays Annual SEC Filing
See More Sigyn Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sigyn Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sigyn Therapeutics and other key companies, straight to your email.

About Sigyn Therapeutics

Sigyn Therapeutics (OTCMKTS:SIGY) is a biotechnology company focused on developing therapeutic technologies intended to address systemic inflammation and infectious diseases. Its primary product candidate, Sigyn Therapy, is designed to remove pro-inflammatory cytokines and pathogen-associated materials from circulating blood, with potential applications in conditions such as cancer and severe infections.

Sigyn Therapy is an investigational blood-purification technology and has not been established as a commercially approved treatment. The company’s development activities center on evaluating the platform’s ability to modulate immune-system responses and support patients whose diseases or treatments may produce harmful inflammatory reactions.

Sigyn Therapeutics is headquartered in the United States and serves the biopharmaceutical and medical-device markets through research and development of its proprietary technology. Publicly available information about the company’s broader commercial operations, geographic reach and current leadership is limited.

View Sigyn Therapeutics Profile